Tempest Therapeutics enters USD 50 million equity purchase deal with Lincoln Park Capital Fund

• Tempest Therapeutics set a $50 million equity line with Lincoln Park Capital to sell common stock in unregistered transactions.
• Initial availability is $25 million, with a further $25 million increase later, subject to conditions.
• Sales can run up to 24 months once a resale registration statement becomes effective; filing due within 10 days of signing.
• Commitment fee paid in stock: 560,356 shares issued at signing, with 350,223 more shares due after full draw of $25 million.
• Issuances capped at 19.99% without shareholder approval unless average sale price meets $1.39; Lincoln Park ownership capped at 4.99%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-349334), on August 13, 2026, and is solely responsible for the information contained therein.